What’s the current market cap for Alto Neuroscience stock?

Alto Neuroscience (ANRO) has a market cap of $798m as of June 20, 2026.

What is the P/E ratio for Alto Neuroscience stock?

The price to earnings (P/E) ratio for Alto Neuroscience (ANRO) stock is 0 as of June 20, 2026.

Does Alto Neuroscience stock pay dividends?

No, Alto Neuroscience (ANRO) stock does not pay dividends to its shareholders as of June 20, 2026.

When is the next Alto Neuroscience dividend payment date?

Alto Neuroscience (ANRO) stock does not pay dividends to its shareholders.

What is the beta indicator for Alto Neuroscience?

Alto Neuroscience (ANRO) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Alto Neuroscience stock | $ANRO Share Price

About Alto Neuroscience

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Ticker

$ANRO

Sector

Health

Primary listing

NYSE

Employees

68

Headquarters

Mountain View, United States

Website

www.altoneuroscience.com

ANRO Metrics

BasicAdvanced

$798m

-

-$2.45

1.25

-

What the Analysts think about ANRO

Analyst ratings (Buy, Hold, Sell) for Alto Neuroscience stock.

Bulls say / Bears say

Alto Neuroscience raised approximately $120 million through a private placement financing in March 2026, providing ample funding to advance multiple Phase 2b trials and extend its cash runway (Reuters)

The company initiated its Phase 2b trial of ALTO-207 in treatment-resistant depression ahead of schedule, demonstrating strong operational execution and accelerating its path toward a potential registrational study (Reuters)

BofA Securities initiated coverage with a Buy rating and a $35 price target, citing positive Phase 2a data for ALTO-207 and confidence in the company’s Precision Psychiatry Platform (Reuters)

Shares fell 8% after the Phase 2 proof-of-concept trial of ALTO-101 for cognitive impairment in schizophrenia failed to meet its primary endpoint, raising doubts about the efficacy of the company’s biomarker-driven approach (Reuters)

First quarter 2026 net loss widened to $26.2 million versus $15.2 million a year ago, with R&D expenses doubling to $20.3 million, underscoring accelerating cash burn and increased operational costs (TradingView)

The $120 million private placement in March 2026, while bolstering cash, carries dilution risk for existing shareholders that may cap near-term upside (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2026.

ANRO Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

ANRO Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

ANRO News

AllArticlesVideos

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Business Wire·5 days ago

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

Business Wire·3 weeks ago

Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award

Business Wire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.